Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$8.04+0.07 (+0.88%)
Close on Nov 18, 2026Market cap $228.52MP/E –Yield –
Arcturus Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Arcturus Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $29.37M, down 76.0% year over year. For fiscal 2025 it was $82.03M, down 46.1% from the year before. The highest annual figure on record is $206.00M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.03M | -46.1% |
| FY2024 | Dec 31, 2024 | $152.31M | -8.7% |
| FY2023 | Dec 31, 2023 | $166.80M | -19.0% |
| FY2022 | Dec 31, 2022 | $206.00M | +1566.8% |
| FY2021 | Dec 31, 2021 | $12.36M | +29.6% |
| FY2020 | Dec 31, 2020 | $9.54M | -54.1% |
| FY2019 | Dec 31, 2019 | $20.79M | +32.0% |
| FY2018 | Dec 31, 2018 | $15.75M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.96M | -89.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.06M | -93.0% |
| Q4 FY2025 | Dec 31, 2025 | $7.20M | -68.4% |
| Q3 FY2025 | Sep 30, 2025 | $17.15M | -58.8% |
| Q2 FY2025 | Jun 30, 2025 | $28.30M | -43.2% |
| Q1 FY2025 | Mar 31, 2025 | $29.38M | -22.7% |
| Q4 FY2024 | Dec 31, 2024 | $22.77M | -26.2% |
| Q3 FY2024 | Sep 30, 2024 | $41.67M | -7.7% |
| Q2 FY2024 | Jun 30, 2024 | $49.86M | +374.0% |
| Q1 FY2024 | Mar 31, 2024 | $38.01M | -52.7% |
| Q4 FY2023 | Dec 31, 2023 | $30.86M | -80.8% |
| Q3 FY2023 | Sep 30, 2023 | $45.14M | +237.6% |
| Q2 FY2023 | Jun 30, 2023 | $10.52M | -61.2% |
| Q1 FY2023 | Mar 31, 2023 | $80.29M | +1431.0% |
| Q4 FY2022 | Dec 31, 2022 | $160.29M | +2666.5% |
| Q3 FY2022 | Sep 30, 2022 | $13.37M | +448.6% |
| Q2 FY2022 | Jun 30, 2022 | $27.09M | +1254.0% |
| Q1 FY2022 | Mar 31, 2022 | $5.24M | +146.5% |
| Q4 FY2021 | Dec 31, 2021 | $5.79M | +158.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.44M | +4.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.00M | -13.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.13M | -19.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.24M | -24.6% |
| Q3 FY2020 | Sep 30, 2020 | $2.33M | -29.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.32M | -77.1% |
| Q1 FY2020 | Mar 31, 2020 | $2.65M | -39.2% |
| Q4 FY2019 | Dec 31, 2019 | $2.97M | -60.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.32M | -3.1% |
| Q2 FY2019 | Jun 30, 2019 | $10.15M | +325.5% |
| Q1 FY2019 | Mar 31, 2019 | $4.35M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.58M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.42M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.39M | – |
See a number that looks wrong?